Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84332 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL22315797 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL7607468 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL20158427 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL15692085 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL12944390 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| Hydrochloric Acid SCHEMBL28466191 | 0.99 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| Hydrochloric Acid SCHEMBL28466185 | 0.99 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL21566843 | 0.97 | SIRT1 (0.41) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL21233409 | 0.93 | HTT (0.38) | SPHK1SPHK2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| EP-3666788-A1 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019031615-A1 | HEMIASTERLIN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES INCLUDING SAME | 大日本住友製薬株式会社 | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247845-A1 | Hemiasterlin Derivatives and Antibody-Drug Conjugates Including Same | FCGRT, QARS1, INHA | NPY4R 1416/4885NPY1R 1934/4885NPY2R 1736/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | NPY4R 1416/4885NPY1R 1934/4885NPY2R 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.